Premium
Treatment of Acute Myeloid Leukaemia with Cytosine Arabinoside and Daunomycin in Combination
Author(s) -
BRINCKER HANS
Publication year - 1972
Publication title -
scandinavian journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0036-553X
DOI - 10.1111/j.1600-0609.1972.tb00998.x
Subject(s) - myeloid leukaemia , medicine , cytosine , complete remission , cytarabine , myeloid , daunorubicin , gastroenterology , myeloid leukemia , leukemia , surgery , chemotherapy , chemistry , dna , biochemistry
19 patients with acute myeloid leukaemia were treated with cytosine arabinoside and daunomycin in combination. The treatment was administered continuously instead of in short cycles. 10 complete and 5 partial remissions were induced. 1 patient was a definite therapeutic failure, while 3 patients did not have adequate trial. Disregarding the latter 3 patients the overall remission frequency was 94 %. 8 of 11 patients more than 60 years old acquired remissions, of which 4 were complete. The median survival was 8 months for the entire series, and the mean duration of the remissions was 5 months.